Market Research Blog

Leading market players are currently focusing on strategic collaborations with various healthcare institutes, universities, governmental agencies, start-up organizations and industry suppliers. This is intended to expand their footprint as well as drive various research and development initiatives.

Besides efforts by market players, initiatives undertaken by regulatory bodies to improve the development and approval process of orphan drug will aid the overall prurigo nodularis treatment market growth. According to FMI, the capsaicin cream segment by drug class is anticipated to gain the momentum significantly contributing towards market growth in the coming years. It is expected to account for over 40% of the market in 2020.

“Increasing research and development activities are expected to boost the growth for prurigo nodularis treatment market. On the other hand, there is high prevalence of unmet needs in the therapeutic domain of rare diseases. This will create impressive growth opportunities for key players contributing towards growth of the market” says the FMI Analyst  

Key Takeaways from Prurigo Nodularis Treatment Market Study

• The demand from the U.S. is expected to rise at a steady pace. It is expected to account for over 91% of the North America market
• France will emerge as a lucrative market, registering above 3% Y-o-Y growth in 2021
• The U.K. and Germany will emerge as other key markets for prurigo nodularis treatment in Europe
• Within East Asia, Japan and China will record rising demand for Prurigo nodularis treatment.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-3339

Who is Winning?

The global market is set to expand steadily over the forecast period, driven by the increasing prevalence of prurigo nodularis, advancements in technology, and adoption of prurigo nodularis treatment drugs which can be used for long term care needs. In addition to this, changing regulatory dynamics and lack of adequate knowledge has constrained the sales of prurigo nodularis treatment drugs.

Product approvals by the U. S. Food and Drug Administration (FDA) for prurigo nodularis treatment drugs are expected to push towards high competition among market players. For Instance, in December 2019, Galderma SA announced the breakthrough therapy designation to its drug Nemolizumab from the U.S. FDA for treatment of prurigo nodularis.

Some of the key market players covered by FMI include Bayer AG, Pfizer Inc., GlaxoSmithKline Plc., Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc., Merck & Co. Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Novartis AG, Celgene Corporation, Galderma SA (Nestle Skin Health Company), VYNE Therapeutics Inc., Trevi Therapeutics Inc. consolidating their positions through mergers, acquisitions and new product launches.

Want more insights?Future Market Insights (FMI) brings the comprehensive research report on forecast revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2015 to 2030. The global prurigo nodularis treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights on prurigo nodularis treatment market on basis of drug class such as corticosteroids (injectable, topical, oral), emollients, capsaicin cream, antihistamines, anticonvulsants, antidepressants, neurokinin 1 receptor (NK1R), opiate receptor antagonists and others. And based on distribution channels such as hospital pharmacies, retail pharmacies and online pharmacies across seven major regions.

Prurigo nodularis treatment Market by CategoryDrug Class

• CorticosteroidsInjectable
  • Topical
  • Oral
  • Emollients
• Capsaicin Cream
• Antihistamines
• Anticonvulsants
• Antidepressants
• Neurokinin 1 Receptor (NK1R)
• Opiate Receptor Antagonists
• Others

Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online sales

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-3339

Region

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa (MEA)

The latest revised report on the ‘neonatal thermoregulation’ market study by Future Market Insights (FMI) offers an exhaustive overview of the global industry while emphasizing on the crucial growth & restraining factors, and demand-supply trajectories across 20+ countries during the forecast period of 2021 to 2031.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-5881

Key Takeaways from Market Study

• The global neonatal thermoregulation industry is predicted to ascend at over 4% CAGR through 2031
• High demand for radiant and wall mount warmers to spur the demand growth
• Closed segment to register impressive demand in terms of modality
• Requirement in hospitals sector to fuel sales
• The United States remains the epicenter in North America neonatal thermoregulation industry
• Germany to sustain on the forefront of the world’s second largest neonatal thermoregulation industry Europe
• Asia Pacific emerges as the fastest growing region during the forecast period
• China, Japan, India, the United Kingdom, France, Italy, Canada, and a few other countries to remain in the limelight for stakeholders

“With the growing focus on reducing morbidity and mortality in newborns, neonatal thermoregulation industry is projected to gain further momentum. Furthermore, increase in number of pediatric & neonatal intensive care units is subject to cater to the demand growth in the near future,” says an FMI analyst.

How is the Increase in Awareness Regarding Newborn Mortality Rates Propelling the Growth?Thermoregulation plays a very crucial role in balancing heat production and heat loss in order to maintain body temperature of newborns within a certain normal range. As not maintaining proper body temperature can be fatal for newborns, demand for neonatal thermoregulation is getting prominent in hospitals and neonatal intensive care units.

For instance, neonatal hyperthermia may occur if proper thermoregulation is not done for a newborn. In this condition, the newborn’s body temperature drops below 36.5 degree Celsius and progressive reduction in body temperature may lead to adverse clinical effects ranging from metabolic stress to death. According to the report titled “Newborns: Improving Survival and Well-Being” published by the World Health Organization (WHO) on 19^th September, 2020, globally 2.4 million neonates died in 2019, while approximately 7000 newborn die every day amounting to 47% of all child deaths under the age of 5 years. Such reports are helping in spreading awareness which in turn is favoring neonatal thermoregulation equipment suppliers.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-5881

Who is Winning in this Space?The global neonatal thermoregulation industry provides with highly competitive environment for key players. In order to leverage the new opportunities, key players are developing advanced and wider range of products.

For instance,

• General Electric Company launched its new Corometrix 250 cx Series, Corometrics 170 Series Fetal Monitor and Mini Telemetry System, and others during the last 5 years
• Natus Medical Incorporated announced the acquisition of Innovative Newborn Care Technology in November, 2020 in order to increase its sales footprint

More Valuable InsightsIn its latest report, FMI offers an unbiased analysis of the neonatal thermoregulation market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of product type (warmer (radiant warmer and wall mount warmer), neonatal incubators (intensive care incubator (hybrid incubator and selective close care incubators), and transport incubator), and neonatal cooling systems), modality (open and closed), and end users (hospitals, paediatric and neonatal intensive care units, and others), across seven major regions of the world (North America, Latin America, Europe, East Asia, South Asia, Oceania, and MEA).

The fundamental factor boosting the Surface disinfectants sales is the increasing occurrences of infections around the world. Direction from International associations such as the Center for Disease Control and Prevention (CDCP), World Health Organization (WHO), and International Federation of Infection Control (IFIC) often encourage disinfection to contain the spread of viruses, which will bode well for the market.

High level disinfectants, preferably in liquid form have emerged as top-selling products in the market, which hospitals will continue as the leading end user. The demand from hospitals segment is forecast to surge at above 6.4% CAGR.

Hospitals are receiving an increasing footfall of patients, besides which focus on ensuring improved patient care and a safe environment for patients as well as healthcare providers is fuelling disinfectant demand. Besides this, the aim at preventing the risk of hospital acquired infections will continue creating sales opportunities.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-1177

Key Takeaways from Surface Disinfectants Market Study

• Surface disinfectants market will register growth at 8.8% CAGR. Sales are expected to surge amid COVID-19 outbreak
• The U.S. will spearhead growth in North America, accounting for maximum sales of surface disinfectants. Increasing healthcare spending will seal the dominance of the U.S.
• Presence of a sophisticated healthcare infrastructure catapults the U.K. as a lucrative market for surface disinfectants
• Germany and France will continue exhibiting high demand, thanks to increasing focus on health and wellness
• Post COVID-19, sales will rise at a remarkable pace in China, Japan, and South Korea

“Rise in prevalence of hospital acquired infections (HAIs), recent COVID-19 outbreak and growing healthcare spending, will continue driving sales,” said a lead analyst at Future Market Insights.

Who is Winning?

To sustain the market, manufacturers are working towards development of innovative products that are not only suitable and required for surgeries in hospital but also for increasing the hygiene level of patients. This is because, when the patient is safe and away from HAIs he will be more co-operative throughout the procedure.

• For an instance, in 2021, P&G launched Microban 24, the new disinfectant brand in the UK, the product range offers unrivalled protection against bacteria in homes, not only initially killing 99.9% of bacteria and select viruses, including COVID-19 virus and flu virus, but continuing to kill bacteria for up to 24 hours, even after multiple touches.
• In 2020, Solvay launched two new products Actizone™ and Amni® Virus-Bac OFF at the forefront of innovation, which will eliminate and keep bacteria and viruses away from many surfaces and avoid cross-contamination.

Valuable Insights into Surface Disinfectants MarketFuture Market Insights, in its new report, offers an unbiased analysis of the global surface disinfectants market, analyzing historical demand from 2016-2020 and forecast statistics for 2021-2031. The study reveals growth projections on the aerosol packaging market on the basis of product type (high-level disinfectants, low level disinfectants, and intermediate level disinfectants), material (aluminum, tin plated steel, plastic, and glass), form (liquid, gel & lotions, wipes, and sprays & foams ) and end user (hospitals, dental clinics, ambulatory surgical centers, diagnostic laboratories, reference laboratories, rehabilitation centers, long term care centers, critical care centers, pharmaceutical & biotechnology companies, and academics and research institutes) across seven regions.

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-1177

Surface Disinfectants Market by CategoryBy Product Type

• High-level Disinfectants
  • Glutaraldehyde
  • Formaldehyde
  • Ortho-phthalaldehyde (OPA)
  • Hydrogen Peroxide
  • Peracetic Acid
  • Chlorine Dioxide
  • Alcohol +QAC
  • Others
• Low Level Disinfectants
  • Phenols
  • Quaternary Ammonium Compounds (QACS)
  • Hydrogen peroxide + peracetic acid
  • Bleach
  • Others
• Intermediate Level Disinfectants
  • Iodophors
  • Sodium Hypochlorite
  • Others

By Form

• Liquid Surface Disinfectants
• Gel & Lotions Surface Disinfectants
• Wipes Surface Disinfectants
• Spray & Foams Surface Disinfectants

By End User

• Hospitals
• Dental Dental Clinics
• Ambulatory Surgical Centers
• Diagnostic Laboratories
• Reference Laboratories
• Rehabilitation Centers
• Long Term Care Centers
• Critical Care Centers
• Pharmaceutical & Biotechnology Companies
• Academics and Research Institutes

By Region

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• MEA

For in-depth competitive analysis, Buy Now – https://www.futuremarketinsights.com/checkout/1177

As per FMI’s analysis, oncology and aesthetics treatment are expected to emerge as key growth engines, followed by ophthalmology applications. Furthermore, preference for low level laser therapy (LLLT) is expected to increase, prompting key manufacturers to introduce a slew of innovative laser therapy devices solutions in the long-run. In 2019, the US Food & Drug Administration approved the Erchonia FX 635, a LLLT device to address whole-body pain, reducing the incidence by nearly 50%.

According to the Cancer Atlas, there were an estimated 18.1 million active cases, with over 9 million cancer deaths in 2018. Additionally, nearly 44 million individuals persons living with cancer that same year who were diagnosed within the previous’ five years. It is projected that this burden is expected to rise by over 60% by 2040. Hence, credible progress is expected to be made in this regard.

Key Takeaways from FMI’s Laser Therapy Devices Market Study

• By device type, gas laser therapy devices to account for more than a quarter of the revenue share through 2021
• A fifth of the total laser therapy devices revenue is accounted for by hospitals, specialty clinics to generate over half of the total share
• Ophthalmology treatment is likely to account for the bulk of the revenue share in the laser therapy devices market
• US and UK to experience high sales amid surging popularity of low-level laser therapy (LLLT)
• High prevalence rates of dermatological disorders to fuel laser therapy device sales across Germany
• Robust healthcare research funding and a flourishing aesthetics industry to pivot French laser therapy devices market growth
• High plastic surgery rates to heighten China’s share in the laser therapy devices market

“Prominent laser therapy devices manufacturers are introducing portable handheld devices in order to enhance the comfort factor for surgeons while administering the appropriate treatment, improving patient outcomes and success rates,” says the FMI analyst.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-5241

Competitive LandscapeBoston Scientific Corporation, IPG Photonics Corporation, Lumenis Ltd., Coherent Inc., Biolitec AG, Hologic Inc., Alma Lasers Ltd., Fotona D.D, Danaher Corporation and Thermo Fisher Scientific Inc. are some prominent laser therapy devices manufacturers as profiled by FMI’s report. New product launches, capacity expansion initiatives and securing regulatory approvals for specific techniques are some key growth strategies.

In 2018, Hologic Inc. received a medical device license issued by Health Canada to market Cynosure’s advanced non-invasive body contouring product called SculpSure^®, a laser treatment device for treating back, inner and outer thighs, and submental area under the chin. This approach destroys fat cells by raising body fat temperature.

Recently, in April 2021, Alma Lasers Ltd. launched the Alma PrimeX^TM platform, a non-invasive approach for body contouring and skin tightening in the abdomen, waist, thighs and buttock areas. It deploys a combination of ultrasound and radiofrequency technologies.

More Insights on the Global Laser Therapy Devices MarketIn its latest report, FMI offers an unbiased analysis of the global laser therapy devices market, providing historical data for the period of 2016-2020 and forecast statistics for the period of 2021-2031. In order to understand the global market potential, its growth, and scope, the market is segmented on the basis of device type (solid-state laser, gas laser, liquid laser and semiconductor laser), end-user (hospitals, ambulatory surgical centers, specialized clinics and other end-users), application (ophthalmology, dermatology, gynecology, dentistry, urology, cardiovascular and others) and region (North America, Latin America, Europe, Japan, APEJ and Middle East & Africa).

Key Segments CoveredDevice Type

• Solid-State Laser
• Gas Laser
• Liquid Laser
• Semiconductor Laser

End-User

• Hospitals
• Specialized Clinics
• Ambulatory Surgical Centers
• Other End-Users

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-5241

Application

• Ophthalmology
• Dermatology
• Gynecology
• Urology
• Cardiovascular
• Others

Region

• North America (US and Canada)
• Latin America (Brazil, Mexico, Argentina and Rest of LATAM)
• Europe (Germany, UK, France, Spain, Italy, Nordics and Rest of Europe)
• Japan
• APEJ (China, India, Malaysia, Thailand, Singapore, Australia and Rest of APEJ)
• Middle East & Africa (GCC, South Africa, Nigeria, Israel and Rest of MEA)

GCC countries have been prioritizing their healthcare sector owing to the increasing population along with a growing burden of geriatric population. There has been a significant increase in the prevalence of lifestyle disorders and other chronic non-communicable diseases in these countries.

This has resulted in the high demand syringes and needles as systems for accurate drug delivery for the treatment of various chronic ailments.

Government reforms and initiatives have been introduced to improve their healthcare systems and various changes have been made to improve the efficiency and quality of healthcare system in the countries. Favorable policies aimed at expansion of healthcare sector will present conducive environment for the growth of the market.

According to an article published in the Saudi Medical Journal, the prevalence of diabetes was around 31.6% in the Kingdom of Saudi Arabia in the year 2017. Furthermore, increasing prevalence of other chronic diseases such as cardiovascular diseases, cancer, and other non-communicable diseases along with diabetes, which require long term care, contribute majorly in the increasing demand for disposable syringes and needles in these countries and will positively impact the market growth over the forecast period.

To remain ahead of your competitors, request for a sample – https://www.futuremarketinsights.com/reports/sample/rep-gb-1874

In February 2021, the Chairman of Department of Health, His Excellency Mohammed Al Hamed visited the Abu Dhabi Medical Devices company’s headquarters factory to oversee the efforts been taken to contribute to the COVID-19 pandemic since the company has made collaborations with various international organizations like UNICEF and COVAX to supply syringes and needles for the vaccination program worldwide.

Such developments not only strengthens the company’s existing portfolio but also help to increase their presence at the regional as well as global level, and helps companies to sustain the increasing competitive pressure. These developments are expected to favor growth of the GCC syringes and needles market.

Key Takeaways from GCC Syringes and Needles Study

• Hypodermic syringes and needles will remain the top-selling product in the market, accounting 87.6% of demand in 2021.
• By usability, the disposable syringes and needles will account for dominant share of 81.3% in the market in 2021.
• By material, the polymer syringes and needles are expected to register high demand. Sales in this category will grow by 8.9% during the forecast period.
• By end user, the hospital segment will account for 66.9% of the market share in 2021.
• By countries, Kingdom of Saudi Arabia (KSA) is anticipated to hold the largest share of 73.6% of the GCC syringes and needles market in 2021.

“In order to cater to surging demand, market players are eyeing for strategic collaborations. Besides this, they are investing in research and development initiatives to strengthen their product portfolio. This is expected to help in the growth of the market over the coming years,” said a lead FMI analyst.

Who is winning?Some of the leading manufacturers of syringes and needles market are focusing on product launch, collaboration and partnership strategies for global expansion objectives, thereby, enhancing their market presence.

• In June 2021, Becton, Dickinson and Company announced that they have received a huge order of 2 billion injection devices which would be used for the vaccination programs around the globe.
• In April 2019, B. Braun Medical Inc., announced the launch of their first FDA approved Heparin Sodium prefilled syringe injection which has attached safety needle for subcutaneous and intravenous use.

The key market players covered by FMI include Becton, Dickinson and Company, Nipro Corporation, Baxter International Inc., B. Braun Melsungen AG, Terumo Corporation, Medtronic PLC, Smiths Group PLC,  Abu Dhabi Medical Devices Company, SAAPP (FZC) LLC. and IBN Sina Medical Factory

Get a Tailored Made Report to Match Your requirements, Ask from Market Research Expert – https://www.futuremarketinsights.com/ask-question/rep-gb-1874

Want more insights?Future Market Insights brings the comprehensive research report on forecasted revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2016 to 2031. The GCC syringes and needles market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader. The study provides compelling insights into syringes and needles market. The syringes and needles market is segmented into two parts based on product (oral and hypodermic) based on usability (disposable and reusable) based on material (glass and polymer) based on end user (hospitals, blood collection centers, diabetic care centers, veterinary care centers, and others)and based on country ( KSA, UAE, Qatar, Bahrain, Oman and Kuwait).